A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The proposed mechanism for the triglyceride (TG) lowering by fibrate drugs is via activation of the peroxisome proliferator-activated receptor-α (PPARα). Here we show that a PPARα agonist, ureido-fibrate-5 (UF-5), ∼200-fold more potent than fenofibric acid, exerts TG-lowering effects (37%) in fat-fed hamsters after 3 days at 30 mg/kg. In addition to lowering hepatic apolipoprotein C-III (apoC-III) gene expression by ∼60%, UF-5 induces hepatic mitochondrial carnitine palmitoyltransferase I (CPT I) expression. A 3-wk rising-dose treatment results in a greater TG-lowering effect (70%) at 15 mg/kg and a 2.3-fold elevation of muscle CPT I mRNA levels, as well as effects on hepatic gene expression. UF-5 also stimulated mitochondrial [3 H]palmitate β-oxidation in vitro in human hepatic and skeletal muscle cells 2.7- and 1.6-fold, respectively, in a dose-related manner. These results suggest that, in addition to previously described effects of fibrates on apoC-III expression and on peroxisomal fatty acid (FA) β-oxidation, PPARα agonists stimulate mitochondrial FA β-oxidation in vivo in both liver and muscle. These observations suggest an important mechanism for the biological effects of PPARα agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · cited 1×
“THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) is so named because of its initial identification as the molecular mediator of the peroxisome proliferation response to a number of chemical stimuli, including fibrates, in mice (15, 17).”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“It has been hypothesized that more potent, directed PPARa agonists would exert more powerful TG-lowering effects (27).”
BackgroundHokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706 · cited 1×
“Elevated plasma triglyceride (TG) concentrations constitute an independent risk factor for coronary artery disease (11, 13).”
BackgroundLee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., & Gonzalez, F. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3012 · Cited by 1,655 · cited 1×
“THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) is so named because of its initial identification as the molecular mediator of the peroxisome proliferation response to a number of chemical stimuli, including fibrates, in mice (15, 17).”
BackgroundChinetti, G., Griglio, S., Antonucci, M., Torra, I. P., Delerive, P., Majd, Z., Fruchart, J.-C., Chapman, J., Najib, J., & Staels, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25573 · Cited by 903 · cited 1×
“Proteins were resolved by electrophoresis on 10% SDS-PAGE gels, transferred onto nitrocellulose membranes, and probed with rabbit polyclonal antibodies against human PPARa (6) or PPARg (kind gift of Bart Staels) by use of the Western Breeze (Novex, San Diego, CA) hybridization/detection system.”
MethodGulick, T., Cresci, S., Caira, T., Moore, D. D., & Kelly, D. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11012 · Cited by 560 · cited 2×
“PPAR responsiveness of these genes in vivo in mice has also been modeled with etomoxir, which inhibits CPT I and is presumed to activate PPARa indirectly by causing accumulation of cellular FA (2, 10).”
BackgroundMartin, G., Schoonjans, K., Lefebvre, A.-M., Staels, B., & Auwerx, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28210 · Cited by 551
Brandt, J. M., Djouadi, F., & Kelly, D. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.23786 · Cited by 456 · cited 5×
“PPAR responsiveness of these genes in vivo in mice has also been modeled with etomoxir, which inhibits CPT I and is presumed to activate PPARa indirectly by causing accumulation of cellular FA (2, 10).”
BackgroundMethodInfluentialAalto-Setälä, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450 · cited 2×
“Because apoC-III is thought to inhibit very low density lipoprotein (VLDL)-TG hydrolysis by lipoprotein lipase and to inhibit uptake of VLDL remnants (1, 26, 32), a reduction in apoC-III synthesis would be predicted to result in a lowering of plasma TG concentrations.”
BackgroundAlterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice
Peters, J. M., Hennuyer, N., Staels, B., Fruchart, J.-C., Fievet, C., Gonzalez, F. J., & Auwerx, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.27307 · Cited by 429 · cited 1×
“It is widely believed that the lipid-lowering effects of fibrates are mediated through PPARa (22).”
Background
Cited by
Thyroid Hormone Regulation of Metabolism
Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00030.2013 · Cited by 2,421
Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects
BONNEFONT, J. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.06.004 · Cited by 637
“…of the CPT genes, a particular attention has been payed on peroxisome proliferator-activated receptors (PPARs), since some of them have been shown to upregulate the expression of genes encoding FAO enzymes (Minnich et al., 2001; Barrero et al., 2003; Djouadi et al., 2003; Gilde et al., 2003).”
BackgroundYoon, M. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.004 · Cited by 336
Sriskanthadevan, S., Jeyaraju, D. V., Chung, T. E., Prabha, S., Xu, W., Skrtic, M., Jhas, B., Hurren, R., Gronda, M., Wang, X., et al. (2015) · Blood · doi:10.1182/blood-2014-08-594408 · Cited by 329
Retinoid X receptors: X-ploring their (patho)physiological functions
Szanto, A., Narkar, V, Shen, Q., Uray, I. P., Davies, P. J. A., & Nagy, L. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401533 · Cited by 302
Identifying off-target effects and hidden phenotypes of drugs in human cells
MacDonald, M. L., Lamerdin, J., Owens, S., Keon, B. H., Bilter, G. K., Shang, Z., Huang, Z., Yu, H., Dias, J., Minami, T., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio790 · Cited by 293
Exercise training increases lipid metabolism gene expression in human skeletal muscle
Tunstall, R. J., Mehan, K. A., Wadley, G. D., Collier, G. R., Bonen, A., Hargreaves, M., & Cameron-Smith, D. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00475.2001 · Cited by 292
Plasticity of skeletal muscle mitochondria: structure and function.
HOPPELER, H., & FL??CK, M. (2003) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200301000-00016 · Cited by 267
Mann, G., Mora, S., Madu, G., & Adegoke, O. A. J. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.702826 · Cited by 261
The Hypermetabolic Response to Burn Injury and Interventions to Modify this Response
Williams, F. N., Herndon, D. N., & Jeschke, M. G. (2009) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2009.05.001 · Cited by 258
Mitochondrial fatty acid oxidation in obesity
Serra, D., Mera, P., Malandrino, M. I., Mir, J. F., & Herrero, L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4875 · Cited by 246
Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation
Liu, Y.-Y., & Brent, G. A. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.11.004 · Cited by 218
“In fat-fed hamsters, PPARα agonist treatment induced CPT-Iα mRNA and reduced serum triglyceride levels [48].”
BackgroundGoto, T., Lee, J.-Y., Teraminami, A., Kim, Y.-I., Hirai, S., Uemura, T., Inoue, H., Takahashi, N., & Kawada, T. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011320 · Cited by 217
Kim, H., Haluzik, M., Asghar, Z., Yau, D., Joseph, J. W., Fernandez, A. M., Reitman, M. L., Yakar, S., Stannard, B., Heron-Milhavet, L., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1770 · Cited by 190
The Role of PPARαActivation in Liver and Muscle
Burri, L., Thoresen, G. H., & Berge, R. K. (2010) · PPAR Research · doi:10.1155/2010/542359 · Cited by 159
“Treatment with a potent PPARα agonist increased the expression of Cpt-1 in hamster soleus muscle [123].”
BackgroundRapid exercise-induced changes in PGC-1α mRNA and protein in human skeletal muscle
Mathai, A. S., Bonen, A., Benton, C. R., Robinson, D. L., & Graham, T. E. (2008) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00847.2007 · Cited by 158
FoxO1 integrates insulin signaling to VLDL production.
Kamagate, A., & Dong, H. H. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6882 · Cited by 127
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Lee, J., Hong, S.-W., Rhee, E.-J., & Lee, W.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.262 · Cited by 87
“PPARα is a transcriptional factor regulating the expression of a number of genes involved in mitochondrial and peroxisomal fatty acid β-oxidation [27,28].”
BackgroundStephens, F. B., Wall, B. T., Marimuthu, K., Shannon, C. E., Constantin‐Teodosiu, D., Macdonald, I. A., & Greenhaff, P. L. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.255364 · Cited by 75
Tunstall, R. J., Mehan, K. A., Hargreaves, M., Spriet, L. L., & Cameron-Smith, D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00473-4 · Cited by 42
“PPAR activation is a potent regulator of skeletal muscle gene expression and FA metabolism [10].”
BackgroundDietary Regulation of Fat Oxidative Gene Expression in Different Skeletal Muscle Fiber Types
McAinch, A. J., Lee, J., Bruce, C. R., Tunstall, R. J., Hawley, J. A., & Cameron‐Smith, D. (2003) · Obesity Research · doi:10.1038/oby.2003.197 · Cited by 42
Dimopoulos, N., Watson, M., Green, C., & Hundal, H. S. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.08.072 · Cited by 36
BAIBA does not regulate UCP-3 expression in human skeletal muscle as a response to aerobic exercise
Morales, F. E., Forsse, J. S., Andre, T. L., McKinley-Barnard, S. K., Hwang, P. S., Anthony, I. G., Tinsley, G. M., Spillane, M., Grandjean, P. W., Ramirez, A., et al. (2017) · Journal of the American College of Nutrition · doi:10.1080/07315724.2016.1256240 · Cited by 23
Okada, M., Sano, F., Ikeda, I., Sugimoto, J., Takagi, S., Sakai, H., & Yanai, T. (2009) · Toxicologic Pathology · doi:10.1177/0192623309336151 · Cited by 17
Metadata
- Authors
- Minnich, A., Tian, N., Byan, L., & Bilder, G.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2001-02-01
- Volume
- 280
- Issue
- 2
- Pages
- E270-E279
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W1504497430
- Cited by
- 192
- References
- 35
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.